Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Nycomed GmbH
In immuno-oncology and beyond, Chinese investors are setting their sights on new targets in the biopharma arena.
The intellectual property, also held by Eureka, may offer a new pathway for treating relapsed MM patients. Sorrento inks cancer partnerships with Karolinska Institutet and Mayo Clinic.
The center is partnering with Obsidian to make autologous TILs work better after being infused back into patients by using IL-15, which may be less toxic than the high-dose IL-2 currently used.
During Q4, device company fundraising totaled $4.2bn; while in vitro diagnostic firms and research tools players raised $6.1bn.
- Medical Devices
- OTC, Consumer
- Specialty Pharmaceuticals
- Other Names / Subsidiaries
- Bradley Pharmaceuticals, Guangdong Techpool Bio-Pharma Co., Ltd.